During the third quarter, Allspring Global Investments Holdings LLC increased its position in Halozyme Therapeutics by 247.8%, acquiring an additional 20,033 shares to total 28,117 shares valued at $2.11 million. This follows a wave of large-scale moves: DLD Asset Management LP initiated a new stake worth $650.25 million; Arrowstreet Capital Limited Partnership boosted its holdings by 127.8% to 2,541,181 shares valued at $132.19 million; Qube Research & Technologies Ltd. built a new position of approximately $51.3 million; Los Angeles Capital Management LLC expanded its position by 951.8% to 973,670 shares valued at $50.65 million; and Norges Bank opened a new stake valued at $45.03 million. Institutional ownership now stands at 97.79%, underscoring strong professional conviction in HALO’s ENHANZE® platform and growth trajectory.

Insider activity over the past 90 days includes the sale of 45,661 shares worth $3.14 million. Director Bernadette Connaughton sold 2,000 shares at an average of $70.25, reducing her stake by 4.75% to 40,123 shares. CEO Helen Torley disposed of 16,569 shares at $68.92 per share, cutting her holdings by 2.28% to 708,719 shares. Insider ownership now accounts for 2.40% of the outstanding stock, suggesting strategic rebalancing rather than a change in long-term conviction given the minimal percentage reductions.

Consensus among eight buy ratings, six holds and one sell yields an average target of $76.45. Recent notable shifts include Zacks Research downgrading HALO from strong-buy to hold; Morgan Stanley trimming its target from $80 to $79 while maintaining an overweight stance; Weiss Ratings upgrading from hold (c+) to buy (b-); Leerink Partners moving from underperform to market perform with a $70 target; and JPMorgan raising its objective from $63 to $65 with a neutral rating. This mixed outlook reflects differing views on the sustainability of reimbursement gains and the impact of ENHANZE® collaborations.

In its most recent quarter, Halozyme reported $1.72 in adjusted EPS, surpassing consensus by $0.09, and generated revenue of $354.26 million, 4.5% above analyst estimates and up 22.1% year-over-year. The company delivered a net margin of 47.9% and an ROE of 156.9%, driven by strong performance in enzyme-based subcutaneous delivery partnerships. Halozyme’s current ratio is 1.59, quick ratio 1.37 and debt-to-equity ratio 1.59. Management forecasts full-year EPS of 4.73, reinforcing confidence in sustained cash generation and reinvestment capacity.